These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37645770)

  • 1. Nigral volume loss in prodromal, early, and moderate Parkinson's disease.
    Langley J; Hwang KS; Huddleston DE; Hu XP
    medRxiv; 2023 Aug; ():. PubMed ID: 37645770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
    PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nigral diffusivity, but not free water, correlates with iron content in Parkinson's disease.
    Langley J; Huddleston DE; Hu X
    Brain Commun; 2021; 3(4):fcab251. PubMed ID: 34805996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease.
    Huddleston DE; Langley J; Sedlacik J; Boelmans K; Factor SA; Hu XP
    Hum Brain Mapp; 2017 May; 38(5):2627-2634. PubMed ID: 28240402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion tensor imaging of nigral degeneration in Parkinson's disease: A region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis.
    Schwarz ST; Abaei M; Gontu V; Morgan PS; Bajaj N; Auer DP
    Neuroimage Clin; 2013; 3():481-8. PubMed ID: 24273730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
    Xing Y; Sapuan AH; Martín-Bastida A; Naidu S; Tench C; Evans J; Sare G; Schwarz ST; Al-Bachari S; Parkes LM; Kanavou S; Raw J; Silverdale M; Bajaj N; Pavese N; Burn D; Piccini P; Grosset DG; Auer DP
    Mov Disord; 2022 May; 37(5):1028-1039. PubMed ID: 35165920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
    Kashihara K; Shinya T; Higaki F
    J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromelanin-sensitive MRI correlates of cognitive and motor function in Parkinson's disease with freezing of gait.
    Huddleston DE; Chen X; Hwang K; Langley J; Tripathi R; Tucker K; McKay JL; Hu X; Factor SA
    medRxiv; 2023 Jul; ():. PubMed ID: 37461735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.
    Kashihara K; Shinya T; Higaki F
    Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
    Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
    Siderowf A; Concha-Marambio L; Lafontant DE; Farris CM; Ma Y; Urenia PA; Nguyen H; Alcalay RN; Chahine LM; Foroud T; Galasko D; Kieburtz K; Merchant K; Mollenhauer B; Poston KL; Seibyl J; Simuni T; Tanner CM; Weintraub D; Videnovic A; Choi SH; Kurth R; Caspell-Garcia C; Coffey CS; Frasier M; Oliveira LMA; Hutten SJ; Sherer T; Marek K; Soto C;
    Lancet Neurol; 2023 May; 22(5):407-417. PubMed ID: 37059509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India.
    Muthane U; Yasha TC; Shankar SK
    Ann Neurol; 1998 Mar; 43(3):283-7. PubMed ID: 9506543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
    Zhang D; Shi Y; Yao J; Zhou L; Wei H; Liu J; Tong Q; Ma L; He H; Wu T
    Mov Disord; 2023 May; 38(5):764-773. PubMed ID: 36797645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.